Pharma Stock ‘Mattered More Than the Price of a Life,’ Physician Tells Senate Roundtable
Guest Post by Michael Nevradakis, Ph.D. Experts who testified at Sen. Ron Johnson’s COVID-19 roundtable described how regulators stifled data, silenced dissenting views and made it possible for drugmakers to prioritize profits over patients under a system where “the price of the stock mattered more …
Read More